摘要
脑膜转移(LM)是晚期非小细胞肺癌(NSCLC)严重并发症之一,虽然发生率不高,但临床症状表现严重,预后差。近几年,在脑膜相关的临床动物模型的建立、脑脊液遗传特征谱、脑脊液液体活检等重要领域取得实质性进展,但LM的最佳治疗策略尚未达成共识,LM的治疗仍然是NSCLC诊疗的一个难点。现有的治疗手段包括分子靶向治疗、系统化疗、局部放疗、鞘内灌注化疗及免疫治疗等,但LM的疗效仍不满意。本文就非小细胞肺癌脑膜转移的病理生理、发病机制、临床表现、诊断、治疗及预后的最新研究进展进行综述,更好的为临床诊疗提供参考。
Leptomeningeal metastasis(LM)is a fatal complication of advanced non-small cell lung cancer(NSCLC),with poor prognosis and rapid deterioration of performance status.In recent years,substantial progress has been made in key aspects such as the establishment of leptomeningeal-related clinical animal models,characterisation of genetic profiles,cytology and genotyping of cerebrospinal fluid biopsy,but the treatment of LM remains a difficult point in the diagnosis and treatment of NSCLC.Existing treatments include molecular targeted therapy,systemic chemotherapy,local radiotherapy,intrathecal chemotherapy,and immunotherapy,etc.However,the efficacy of LM is still poor.This review will focus on LM arising from NSCLC with a goal to provide the reader an understanding of the pathophysiology,pathogenesis,clinical presentation,diagnosis,treatment and prognosis.
作者
陆志琴
袁源亮
刘安文
LU Zhiqin;YUAN Yuanliang;LIU Anwen(Department of Oncology,The Second Affiliated of Nanchang University,Nanchang 330006,China;Jiangxi Key Laboratory of Clinical Translational Cancer Research,Nanchang 330006,China;Department of Head and Neck Radiotherapy,Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi 830000,China)
出处
《肿瘤防治研究》
CAS
CSCD
2020年第12期986-991,共6页
Cancer Research on Prevention and Treatment
基金
江西省肿瘤临床转化重点实验室(20171BCD40022)
江西省研究生创新专项资金(YC2019-S087)
2018年CSCO齐鲁研究基金(Y-Q201802-009)
2016年江西省自然基金(20161BBG70210)。
关键词
肺癌
脑膜转移
药物治疗
Lung cancer
Leptomeningeal metastasis
Drug therapy
